Literature DB >> 28738842

Ovarian preservation in adenocarcinoma of the uterine cervix.

Jiansong Zhou1, Yuanyuan Chen2, Ping Zhang3, Hanmei Lou4.   

Abstract

BACKGROUND: An upward trending incidence in cervical adenocarcinoma (ADC) has been reported in many countries. Because non-squamous histology has been associated with increased risk of ovarian metastases (OM), bilateral oophorectomy is commonly performed for ADC without due consideration for ovarian preservation, degrading the quality of life for young premenopausal patients.
METHODS: Subjects were patients with International Federation of Gynecology and Obstetrics (FIGO) stage I-IIB cervical ADC who underwent radical hysterectomy, including pelvic lymphadenectomy and bilateral salpingo-oophorectomy at our institution between Oct. 2006 and Sept. 2014. Clinicopathologic variables were studied by univariate and multivariate analyses.
RESULTS: Of the 312 patients enrolled in the study, 14 patients (4.5%) developed OM. Multivariate analysis revealed that uterine corpus involvement (odds ratio [OR] 5.178, p = 0.019), parametrial involvement (OR 14.125, p = 0.005) and vaginal infiltration (OR 4.167, p = 0.047) were independently associated with metastasis. OM had no effect on either relapse-free survival (95% confidence interval [CI]: 0.077-4.095, p = 0.57) or overall survival (95% CI: 0.893-9.820, p = 0.076).
CONCLUSION: Cervical ADC is associated with an increased risk of OM. Ovarian preservation surgery in cervical ADC may be safe for young patients at an early FIGO stage without deep stromal, endometrial or perineural invasion, and particularly without uterine corpus invasion, parametrial involvement and infiltration into the vagina.

Entities:  

Keywords:  Adenocarcinoma; Ovarian metastasis; Ovarian preservation

Mesh:

Year:  2017        PMID: 28738842      PMCID: PMC5525268          DOI: 10.1186/s13048-017-0339-y

Source DB:  PubMed          Journal:  J Ovarian Res        ISSN: 1757-2215            Impact factor:   4.234


Background

Invasive cervical cancer (ICC) ranks as the third most common malignancy and is the fourth leading cause of female cancer deaths worldwide [1]. Patients with FIGO early stage disease generally undergo radical hysterectomy and pelvic lymphadenectomy. However, bilateral oophorectomy is not part of standard surgical management of ICC. Currently, an upward trend in the incidence of adenocarcinoma (ADC) has been reported in many countries, particularly among women under the age of 40 [2-5]. Since Shimada et al. and Ronnett et al. have reported that approximately 5% of women with cervical ADC are at an increased risk of ovarian metastases (OM), which occurs in about half of ADC cases post-hysterectomy [6, 7], oophorectomy is commonly performed in ADC to preclude OM. Ovarian preservation, which is beneficial to the physiologic and psychosexual well-being of premenopausal women affected by cervical cancer, remains a challenge in clinical practice. Some believe that non-squamous histology should be a deterrent to ovarian transposition [8]. Others advocate lymphovascular space invasion (LVSI), deep stromal invasion (DSI) and uterine corpus involvement as contraindications [8, 9]. The aim of the present retrospective study was to identify the clinicopathological factors associated with OM in ADC.

Methods

Patients

Study participants were patients diagnosed with FIGO stage I–IIB invasive ADC of the uterine cervix and treated by radical hysterectomy, bilateral salpingo-oophorectomy and pelvic lymphadenectomy at the Zhejiang Cancer Hospital, Zhejiang Province, China between Oct. 2006 and Sep. 2014. Clinical data were extracted from the institution’s electronic databases after informed consent was obtained from all patients. The Medical Ethics Committee of Zhejiang Cancer Hospital approved the study. The following clinical and histological parameters were evaluated in relation to OM: age at surgery, FIGO stage, bulky tumor size (>4 cm), differentiation, morphology, DSI (≥2/3), LVSI, parametrial involvement, uterine corpus involvement, endometrial invasion, fallopian tube invasion, vaginal infiltration, perineural invasion (PNI) and para-aortic/pelvic lymph node status.

Statistical analysis

Statistical analyses were performed with the SPSS 16.0 software package (IBM, Armonk, NY, USA). P-values <0.05 were considered statistically significant. Summary statistics are presented as frequencies and percentages. The Pearson χ2 test was used to assess the association between clinicopathologic parameters and the presence of OM. Multivariate analysis was used to detect independent risk factors for OM and results are presented as odds ratios (OR).

Results

Patient characteristics

A total of 312 ADC patients were enrolled into the study, including 9 patients (2.9%) with FIGO stage IA, 217 patients (69.6%) with stage IB, 74 patients (23.7%) with stage IIA and 12 patients (3.8%) with stage IIB. The median age of patients was 46 years (range: 19–73 years). OM were diagnosed in 14 patients (4.5%). A summary of patients with OM is shown in Table 1. OM occurred in five of the 217 patients (2.3%) in stage IB, eight of the 74 patients (10.8%) in stage IIA and one of the 12 patients (8.3%) in stage IIB. A significantly higher incidence of OM was observed in stage II ADC (p = 0.002, OR 9.899). The mean age of these 14 patients was 46 (range 32–68) years. Potential risk factors for OM are listed in Table 2. Patients with OM were frequently observed by univariate analysis with FIGO stage I or II (p = 0.002), DSI (p = 0.002), uterine corpus involvement (p < 0.001), endometrial invasion (p < 0.001), parametrial involvement (p < 0.001), PNI (p = 0.011), fallopian tube invasion (p < 0.001) or vaginal infiltration (p < 0.001). However, outcomes for patients with OM did not correlate with age at surgery, bulky tumor size, differentiation, morphology, LVSI or lymph node metastasis.
Table 1

Summary of patients with ovarian metastasis

CaseAgeFIGO stageGradeDSIMorphologyUCIEndometrial invasionFallopian tube invasionPerineural invasionLVSIInfiltration to vaginaLymph node metastasis
Para-aorticPelvic
142IIAG3+Endophytic+++++
243IIAG2+Exophytic++
362IIAG2+Endophytic++++
449IBG3+Exophytic++++
541IIAG2+Exophytic+++
651IIBG2+Exophytic
736IIAG3Exophytic++
855IIAG2Exophytic++
948IIAG2Endophytic+++
1036IBG3Exophytic+
1143IBG2Exophytic++
1268IBG3Endophytic+++++
1343IIAG2+Endophytic+++++
1432IBG3+Endophytic+++

DSI deep stromal invasion

UCI uterine corpus involvement

LVSI lymphovascular space invasion

Table 2

Univariate and multivariate analyses of risk factors for ovarian metastasis in patients with cervical adenocarcinoma

ParameterN (%)Univariate analysesMultivariate analyses
Total no. of patients enrolled312Ovarian metastasisOdds ratio p-value
YesNo p-value
Age at surgery
  < 60282 (90.4)122700.544
  ≥ 6030 (9.6)228
FIGO stage
 I226 (72.4)52210.002*2.4450.243
 II86 (27.6)977
Tumor diameter (cm)
  < 4221 (70.8)72140.079
  ≥ 491 (29.2)784
Differentiation
 G1 + G2191 (61.2)81820.756
 G3121 (38.8)6115
Tumour morphology
 Exophytic109 (34.9)81010.075
 Endophytic203 (65.1)6197
Deep stromal invasion
 Superficial (<2/3)210 (67.3)42060.002*1.3070.743
 Deep (≥2/3)102 (32.7)1092
Parametrial invasion
 Negative296 (94.9)82885.80E-11*14.1250.005*
 Positive16 (5.1)610
Lymph-vascular space invasion
 Negative197 (63.1)71900.297
 Positive115 (36.9)7108
Pelvic node status
 Negative227 (72.8)102170.909
 Positive85 (27.2)481
Fallopian tube invasion
 Negative302 (96.8)102923.51E-8*1.8370.338
 Positive10 (3.2)46
Para-aortic node status
 Negative305 (97.8)132920.205
 Positive7 (2.2)16
Infiltration to vagina
 Yes58 (18.6)8501.48E-4* 4.1670.047*
 No254 (81.4)6248
Endometrial invasion
 Negative300 (96.2)112894.65E-4*3.1560.213
 Positive12 (3.8)39
Uterine corpus invasion
 Negative252 (80.8)52471.20E-5* 5.1780.019*
 Positive60 (19.2)951
Perineural invasion
 Negative271 (86.9)92620.011*0.2730.174
 Positive41 (13.1)536

FIGO The International Federation of Gynecology and Obstetrics

* p < 0.05

Summary of patients with ovarian metastasis DSI deep stromal invasion UCI uterine corpus involvement LVSI lymphovascular space invasion Univariate and multivariate analyses of risk factors for ovarian metastasis in patients with cervical adenocarcinoma FIGO The International Federation of Gynecology and Obstetrics * p < 0.05 Furthermore, multivariate analysis identified uterine corpus involvement (OR 5.178, p = 0.019), parametrial involvement (OR 14.125, p = 0.005) and vaginal infiltration (OR 4.167, p = 0.047) to be independently associated with OM. Meanwhile, OM had no effect on either relapse-free survival (95% confidence interval [CI]: 0.077–4.095, p = 0.57) or overall survival (95% CI: 0.893–9.820, p = 0.076) (Fig. 1).
Fig. 1

Overall survival of 14 patients positive for ovarian metastases (OM) and 298 patients negative for OM. OM had no effect on overall survival (95% CI: 0.893–9.820, p = 0.076)

Discussion

ICC is still a leading cause of cancer-related deaths in women worldwide. For decades, an upward trending incidence of ADC has been reported in many countries, accounting for approximately one-quarter of all ICC cases [10]. ADC is distinguished from squamous cell carcinoma (SCC) by virtue of different human papillomavirus types, patterns of spread, prognosis and recurrence [11, 12]. Furthermore, published data has revealed that the incidence of OM in the presence of non-squamous histology is increased compared to SCC [8]; hence, bilateral oophorectomy is frequently recommended in cases of ADC. Overall survival of 14 patients positive for ovarian metastases (OM) and 298 patients negative for OM. OM had no effect on overall survival (95% CI: 0.893–9.820, p = 0.076) Approximately 50% of ICC patients are premenopausal and under 45 years old [13]. Ovarian preservation has proven invaluable for improving the quality of life of these young women. According to the literature, ovarian metastatic incidence occurs more frequently among patients with ADC than in those with SCC, ranging between 1.7% and 18.9% and from 0.4% to 1.3%, respectively [6, 8, 14, 15]. Moreover, Ronnett et al. reported that in about half of ADC cases, metastases occurred post-hysterectomy [7]. Therefore, the benefits of preserving hormonal function may be offset by a potentially higher risk of recurrence in ADC. Conversely, Gubbala et al. concluded that ovarian transposition resulted in significant preservation of ovarian function with negligible risk of metastases to the transposed ovaries despite the common incidence of ovarian cysts [16]. Lyu et al. found that ovarian preservation provided oncological safety for young women with stage I cervical adenocarcinoma [17]. In the present study, the incidence of OM in ADC was 4.5% (14/312), and a significantly higher incidence of OM was observed in stage II compared to stage I cancers. The selection of premenopausal patients who would benefit from ovarian preservation to improve the quality of life is challenging. A thorough understanding of the risk factors involved would be of great value for following a patient with ovarian preservation postoperatively [17]. The majority of cases we have examined have been diagnosed through primary radical surgery with bilateral oophorectomy. However, in the past two decades, increasing attention has been paid to OM and contributing factors. Age, FIGO stage, histology, lymph node metastases, DSI, LVSI, bulky tumor size, parametrial invasion and corpus uteri invasion have been determined to be independent risk factors for OM in ADC [8, 18–21]. In our study, we identified FIGO stage, DSI, uterine corpus invasion, endometrial invasion, parametrial involvement, PNI, fallopian tube invasion and vaginal infiltration as significantly related to OM in ADC. In our multivariate analysis, uterine corpus invasion, parametrial involvement and vaginal infiltration were independent risk or protective factors for OM in patients with ADC. The occurrence of OM had no significant relationship to either relapse-free survival or overall survival. The routes by which ICC spreads to the ovary remain unclear. Wu et al. proposed that lymphatic spread and transtubal implantation may be possible pathways of metastases from the cervix to the ovaries [18]. Tabata et al. reported that OM may take place via hematogenous spread of cervical carcinoma [22]. Further research efforts will be required to establish the pathways involved.

Conclusions

In conclusion, we found that cervical ADC is associated with a relatively higher risk of OM. Based on our data, we suggest that ovarian preservation may be safely performed in young patients with early FIGO stage cervical ADC without deep stromal invasion, endometrial invasion or perineural invasion, and particularly in the absence of uterine corpus invasion, parametrial involvement and infiltration to the vagina.
  22 in total

1.  Ovarian metastasis in carcinoma of the uterine cervix.

Authors:  Muneaki Shimada; Junzo Kigawa; Ryuichiro Nishimura; Satoshi Yamaguchi; Kazuo Kuzuya; Toru Nakanishi; Mitsuaki Suzuki; Tsunekazu Kita; Tsuyoshi Iwasaka; Naoki Terakawa
Journal:  Gynecol Oncol       Date:  2005-11-21       Impact factor: 5.482

2.  Development of criteria for ovarian preservation in cervical cancer patients treated with radical surgery with or without neoadjuvant chemotherapy: a multicenter retrospective study and meta-analysis.

Authors:  Ting Hu; Li Wu; Hui Xing; Ru Yang; Xiong Li; Kecheng Huang; Yao Jia; Qinghua Zhang; Zhilan Chen; Shaoshuai Wang; Dan Liu; Xiaobing Han; Zhongqiu Lin; Pengpeng Qu; Hongbing Cai; Xiaojie Song; Xiaoyu Tian; Hui Wang; Shixuan Wang; Xing Xie; Shuang Li; Ding Ma
Journal:  Ann Surg Oncol       Date:  2012-10-03       Impact factor: 5.344

3.  Ovarian preservation in young patients with stage I cervical adenocarcinoma: a surveillance, epidemiology, and end results study.

Authors:  Jiangtao Lyu; Tingting Sun; Xianjie Tan
Journal:  Int J Gynecol Cancer       Date:  2014-10       Impact factor: 3.437

4.  A study of risk factors for ovarian metastases in stage Ib-IIIb cervical carcinoma and analysis of ovarian function after a transposition.

Authors:  R Yamamoto; K Okamoto; T Yukiharu; M Kaneuchi; H Negishi; N Sakuragi; S Fujimoto
Journal:  Gynecol Oncol       Date:  2001-08       Impact factor: 5.482

5.  Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study).

Authors:  F Landoni; V Zanagnolo; L Lovato-Diaz; A Maneo; R Rossi; A Gadducci; S Cosio; T Maggino; E Sartori; C Tisi; P Zola; F Marocco; E Botteri; K Ravanelli
Journal:  Int J Gynecol Cancer       Date:  2007-02-16       Impact factor: 3.437

6.  Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy.

Authors:  T Irie; J Kigawa; Y Minagawa; H Itamochi; S Sato; R Akeshima; N Terakawa
Journal:  Eur J Surg Oncol       Date:  2000-08       Impact factor: 4.424

7.  A multivariate analysis of blood vessel and lymph vessel invasion as predictors of ovarian and lymph node metastases in patients with cervical carcinoma.

Authors:  N Sakuragi; N Takeda; H Hareyama; T Fujimoto; Y Todo; K Okamoto; M Takeda; S i Wada; R Yamamoto; S Fujimoto
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

8.  International trends in incidence of cervical cancer: II. Squamous-cell carcinoma.

Authors:  A P Vizcaino; V Moreno; F X Bosch; N Muñoz; X M Barros-Dios; J Borras; D M Parkin
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

9.  Uterine corpus involvement as well as histologic type is an independent predictor of ovarian metastasis in uterine cervical cancer.

Authors:  Min-Jeong Kim; Hyun Hoon Chung; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

Review 10.  The need for laparoscopic ovarian transposition in young patients with cervical cancer undergoing radiotherapy.

Authors:  Hariyono Winarto; Eva Febia; Gatot Purwoto; Laila Nuranna
Journal:  Int J Reprod Med       Date:  2013-12-03
View more
  6 in total

1.  [Pregnancy-preserving and maternal-fetal management in a patient with rare large cell neuroendocrine carcinoma of the uterine cervix].

Authors:  Dai Geyang; Chen Gaowen; L I Xiaoxuan; Zheng Youhong; Wang Yuan; Li Xingsong; L I Jing; Zhou Jing; Xie Yu; Wang Yifeng
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-01-30

2.  Influence of ovarian-sparing surgery and ovariectomy on prognosis in early cervical adenocarcinoma: a systematic review and meta-analysis.

Authors:  Jiangxin Sheng; Yunhua Yi; Jichan Nie
Journal:  Gland Surg       Date:  2022-06

3.  Factors Associated with Patient Survival in Clear Cell Adenocarcinoma of the Cervix: A Single-Center Experience in China.

Authors:  Ting Wang; Zhiying Lu; Xiaodan Zhang; Keqin Hua
Journal:  Int J Gen Med       Date:  2022-05-03

4.  Clear Cell Adenocarcinoma of Uterine Cervix: A Single Institution Retrospective Experience.

Authors:  Zhimin Liu; Junyun Li; Haifeng Gu; Hua Tu; Guochen Liu; Jihong Liu
Journal:  Front Oncol       Date:  2020-11-13       Impact factor: 6.244

Review 5.  Tumor Staging of Endocervical Adenocarcinoma: Recommendations From the International Society of Gynecological Pathologists.

Authors:  Kay J Park; Andres Roma; Naveena Singh; C Blake Gilks; Esther Oliva; Nadeem Abu-Rustum; Pedro T Ramirez; W Glenn McCluggage
Journal:  Int J Gynecol Pathol       Date:  2021-03-01       Impact factor: 3.326

6.  Adenosquamous Carcinoma of the Cervix: A Population-Based Analysis.

Authors:  Pengfei Cui; Xiaofeng Cong; Chen Chen; Lei Yang; Ziling Liu
Journal:  Front Oncol       Date:  2021-07-22       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.